April 29, 2020 / 5:30 AM / a month ago

BRIEF-Vivoryon Says Morphosys Has Not Exercised Exclusive Option

April 29 (Reuters) - VIVORYON THERAPEUTICS AG:

* ANNOUNCES OUTCOME OF EXCLUSIVE OPTION DEAL WITH MORPHOSYS

* MORPHOSYS HAS NOT EXERCISED EXCLUSIVE OPTION TO LICENSE VIVORYON’S SMALL MOLECULE QPCTL INHIBITORS IN IMMUNO-ONCOLOGY FIELD Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below